Wide Ranks

LUNG

Pulmonx Corporation

6.30

Top Statistics
Market Cap 248 M Forward PE -3.99 Revenue Growth 15.40 %
Current Ratio 7.70 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins -72.01 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -3.58 Enterprise / Revenue 2.48 Price To Sales Trailing12 Months 3.14
Profitability
Profit Margins -72.01 % Operating Margins -69.30 %
Balance Sheet
Total Cash 107 M Total Cash Per Share 2.73 Total Debt 55 M
Total Debt To Equity 59.42 Current Ratio 7.70 Book Value Per Share 2.38
All Measures
Short Ratio 368.00 % Message Board Id finmb_8446085 Shares Short Prior Month 1 M
Return On Equity -0.5199 City Redwood City Uuid e6c2e6bc-5375-39f3-b953-9a49b1ec8ea8
Previous Close 6.46 First Trade Date Epoch Utc 1 B Book Value 2.38
Beta 0.6840 Total Debt 55 M Volume 168371
Price To Book 2.65 Fifty Two Week Low 5.46 Total Cash Per Share 2.73
Total Revenue 79 M Shares Short Previous Month Date 1 B Target Median Price 14.00
Max Age 86400 Sand P52 Week Change 0.3133 Operating Margins -69.30 %
Target Mean Price 13.50 Net Income To Common -57107000 Short Percent Of Float 0.0302
Implied Shares Outstanding 39 M Trailing Peg Ratio None Last Fiscal Year End 1 B
Average Daily Volume10 Day 191850 Average Volume10days 191850 Total Cash 107 M
Next Fiscal Year End 1 B Revenue Per Share 2.04 Held Percent Insiders 0.0501
Ebitda Margins -69.36 % Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 6.46 Target Low Price 10.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 6.96 Open 6.48
Free Cashflow -14473875 State CA Dividend Yield 0.00 %
Return On Assets -0.2004 Time Zone Short Name EST Trailing Eps -1.47
Day Low 6.26 Address1 700 Chesapeake Drive Shares Outstanding 39 M
Price Hint 2 Target High Price 17.00 Website https://pulmonx.com
52 Week Change -0.4220 Average Volume 230826 Forward Eps -1.60
Recommendation Key none Compensation As Of Epoch Date 1 B Quick Ratio 656.30 %
Is_sp_500 False Regular Market Day High 6.65 Profit Margins -72.01 %
Debt To Equity 59.42 Fifty Two Week High 14.84 Day High 6.65
Shares Short 842687 Regular Market Open 6.48 Industry Key medical-devices
Earnings Growth 0.00 % Enterprise To Revenue 2.48 Revenue Growth 15.40 %
Shares Percent Shares Out 0.0213 Operating Cashflow -33256000 Currency USD
Time Zone Full Name America/New_York Market Cap 248 M Is_nasdaq_100 False
Zip 94063 Quote Type EQUITY Industry Medical Devices
Long Name Pulmonx Corporation Regular Market Day Low 6.26 Held Percent Institutions 0.9490
Current Price 6.30 Enterprise To Ebitda -3.58 Financial Currency USD
Current Ratio 7.70 Gross Margins 74.16 % Industry Disp Medical Devices
Number Of Analyst Opinions 6 Country United States Float Shares 37 M
Two Hundred Day Average 7.72 Enterprise Value 196 M Price To Sales Trailing12 Months 3.14
Forward PE -3.99 Regular Market Volume 168371 Ebitda -55003000
Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases.

The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.

It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves.

The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally.

The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013.

Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.